Priothera SAS

Priothera SAS is a privately held, clinical-stage biopharmaceutical company headquartered in Saint-Louis, France. The company is focused on extending and enhancing the quality of life for patients with hematological malignancies, with a particular emphasis on acute myeloid leukemia (AML). Its stated vision is to radically transform treatment by pioneering innovative immune modulators that can enhance the curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) and CAR T cell therapy. The company's lead investigational drug is mocravimod, an immune modulator being developed to address critical challenges in allo-HCT maintenance strategies. Priothera aims to enhance the graft-versus-leukemia (GvL) effect while simultaneously reducing graft-versus-host disease (GvHD), a common and serious complication of stem cell transplantation. The company is conducting the MO-TRANS study to evaluate mocravimod in this setting. Priothera was founded by a team of globally acknowledged scientists and drug development leaders, including Florent Gros (CEO), Stephan Oehen (COO), and Brice Suire (CFO). The leadership team also includes Nigel Clark as Chief Business Officer and Dr. Jens Hasskarl as Chief Medical Officer. The founders bring extensive experience from organizations such as Novartis, Nestlé, and Cytos Biotechnology. As a private company, Priothera is backed by venture capital and is not listed on any public stock exchange. Its operations are primarily in France, with a focus on developing therapies for the global market, particularly the United States and Europe. The company's pipeline includes mocravimod and other investigational immune modulators aimed at improving outcomes in hematopoietic cell transplantation and CAR T cell therapy.

Priothera SAS was founded by Florent Gros, Stephan Oehen, and Brice Suire, a team of scientists and drug development leaders with extensive experience in biotechnology and pharmaceuticals. The company is headquartered in Saint-Louis, France, and operates as a clinical-stage biopharmaceutical company focused on hematological malignancies. The founding team's vision was to make a difference in acute myeloid leukemia (AML) patient care by developing innovative immune modulators. Florent Gros, the CEO, brought experience from Novartis Venture Funds, where he led investments in numerous start-up companies, as well as roles at Nestlé and Pasteur Merieux Connaught. Stephan Oehen, the COO, is an immunologist with a background in autoimmunity, transplantation, and inflammation, having held leadership positions at Cytos Biotechnology and Novartis. Brice Suire, the CFO, completed the founding trio. The company's lead program, mocravimod, was in-licensed or acquired and is being developed to enhance the graft-versus-leukemia effect while reducing graft-versus-host disease in allogeneic hematopoietic cell transplantation (allo-HCT). Priothera is conducting the MO-TRANS study to evaluate mocravimod in this indication. The company's pipeline also explores applications in CAR T cell therapy. As a private company, Priothera has raised capital from venture investors to advance its clinical programs. The leadership team has been expanded with the appointments of Nigel Clark as Chief Business Officer and Dr. Jens Hasskarl as Chief Medical Officer. The company continues to pursue its mission of extending and enhancing the quality of life for patients with hematological malignancies.

• Priothera SAS founded by Florent Gros, Stephan Oehen, and Brice Suire

• Mocravimod identified as lead investigational immune modulator for allo-HCT

• MO-TRANS study initiated to evaluate mocravimod in allo-HCT

• Nigel Clark appointed Chief Business Officer

• Dr. Jens Hasskarl appointed Chief Medical Officer

Clinical-stage biopharmaceutical company developing innovative immune modulators to enhance curative potential of allo-HCT and CAR T cell therapy in hematological malignancies.

• Mocravimod

  Investigational immune modulator designed to enhance graft-versus-leukemia effect while reducing graft-versus-host disease in allogeneic hematopoietic cell transplantation.

1. 1Priothera | Improving patient’s lives by delivering an innovative immune modulatorpriothera.com
2. 2Our Leadership Team | Priotherapriothera.com
3. 3Priothera SAS (France) - Wikidatawikidata.org
4. 4Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)prnewswire.com